

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**  
**(Case No. 98,365-B1)**

**PATENT**

In re Application of:

**Rodgers and diZerega**

Serial No.: **To be assigned**

Filed: **Herewith**

For: **Method for Accelerating Bone,  
Cartilage, and Connective Tissue  
Growth**

Art Unit: **To be assigned**

Examiner: **To be assigned**

Asst. Commissioner for Patents  
BOX Application  
Washington, D.C. 20231

**COMPLIANCE WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**


Sir,

As required by 37 C.F.R. 1.821(f), the content of the sequence listing paper copy and computer readable copy are the same.

Respectfully submitted,  
**McDonnell Boehnen Hulbert & Berghoff**

Dated: January 30, 2001

By:

  
**David Harper**  
Reg. No. 42,636



<220>  
<223> Description of Artificial Sequence: AII (1-7)

<400> 4  
Asp Arg Val Tyr Ile His Pro  
1 5

<210> 5  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: AII (2-7)

<400> 5  
Arg Val Tyr Ile His Pro  
1 5

<210> 6  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: AII (3-7)

<400> 6  
Val Tyr Ile His Pro  
1 5

<210> 7  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: AII (5-8)

<400> 7  
Ile His Pro Phe  
1

<210> 8  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: AII (1-6)

<400> 8  
Asp Arg Val Tyr Ile His  
1 5

<210> 9  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: AII (1-5)

<400> 9  
Asp Arg Val Tyr Ile  
1 5

<210> 10  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: AII (1-4)

<400> 10  
Asp Arg Val Tyr  
1

<210> 11  
<211> 3  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: AII (1-3)

<400> 11  
Asp Arg Val  
1

<210> 12  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: AII analogue

<220>  
<221> MOD\_RES  
<222> (2)  
<223> Nle

<400> 12  
Arg Xaa Tyr Ile His Pro Phe  
1 5

<210> 13  
<211> 7



<223> Xaa at position 2 can be Val, Ala, Leu, Nle, Ile, Gly, Pro, Aib, Acp, or Tyr

<220>

<221> UNSURE

<222> (4)

<222> Xaa at position 4 can be Ile, Ala, Leu, Nle, Val,  
or Gly

<400> 16

Xaa Xaa Tyr Xaa His Pro Phe  
1 5

<210> 17

<211> 7

<212> PRT

<213> Artificial Sequence

**<220>**

<223> Description of Artificial Sequence: AII analogue

<400> 17

Arg Val Tyr Gly His Pro Phe  
1 5

<210> 18

<211> 7

&lt;212&gt; PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII analogue

<400> 18

Arg Val Tyr Ala His Pro Phe  
1 5

<210> 19

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII analogue 1

<400> 19

Asp Arg Val Tyr Val His Pro Phe  
1 5

<210> 20

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: AII analogue 2







5

```
<400> 30
Pro Arg Val Tyr Ile His Pro Phe
  1             5
```

<220>  
<223> Description of Artificial Sequence: AII analogue 13

```
<400> 31
Asp Arg Pro Tyr Ile His Pro Phe
  1                               5
```

```
<210> 32
<211> 8
<212> PRT
<213> Artificial Sequence
```

<220>  
<223> Description of Artificial Sequence: AII analogue 14

```
<220>
<221> MOD_RES
<222> (4)
<223> PHOSPHORYLATION
```

```
<400> 32
Asp Arg Val Tyr Ile His Pro Phe
  1                               5
```

```
<210> 33
<211> 8
<212> PRT
<213> Artificial Sequence
```

<220>  
<223> Description of Artificial Sequence: AII analogue 15

```
<220>  
<221> MOD_RES  
<222> (3)  
<223> Nle
```

[illegible]

<400> 33  
Asp Arg Xaa Tyr Ile His Pro Phe  
1 5

<210> 34  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: AII analogue 16

<220>  
<221> MOD\_RES  
<222> (5)  
<223> Nle

<400> 34  
Asp Arg Val Tyr Xaa His Pro Phe  
1 5

<210> 35  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: AII analogue 17

<220>  
<221> MOD\_RES  
<222> (4)  
<223> homo Ser

<400> 35  
Asp Arg Val Ser Tyr Ile His Pro Phe  
1 5

<210> 36  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial  
Sequence: p-aminophenylalanine 6 AII

<220>  
<221> MOD\_RES  
<222> (6)  
<223> p-aminophenylalanine

<400> 36  
Asp Arg Val Tyr Ile Xaa Pro Phe  
1 5

<210> 37  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:angiotensin I

<400> 37  
Asp Arg Val Tyr Ile His Pro Phe His Leu  
1 5 10

<210> 38  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<221> MOD\_RES  
<222> (2)  
<223> Orn

<220>  
<223> Description of Artificial Sequence:GSD37B:  
Orn2-AII

<400> 38  
Asp Xaa Val Tyr Ile His Pro Phe  
1 5

<210> 39  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:GSD28: Ile8-AII

<400> 39  
Asp Arg Val Tyr Ile His Pro Ile  
1 5

<210> 40  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:1GD:  
Ala4-AII(1-7)

<400> 40  
Asp Arg Val Ala Ile His Pro  
1 5

<210> 41

<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:2GD:  
Pro3-AII(1-7)

<400> 41  
Asp Arg Pro Tyr Ile His Pro  
1 5

<210> 42  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Gly1-AII

<400> 42  
Gly Arg Val Tyr Ile His Pro Phe  
1 5

<210> 43  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial  
Sequence:GSD38B:Citron2-AII

<220>  
<221> MOD\_RES  
<222> (2)  
<223> Citron

<400> 43  
Asp Xaa Val Tyr Ile His Pro Phe  
1 5

<210> 44  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial  
Sequence:Pro3Ala4-AII(1-7)

<400> 44  
Asp Arg Pro Ala Ile His Pro  
1 5

<210> 45

